Genomika - Company finances
|
EUR
|
2019
From: 2019-09-13
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|
|
Financial data
|
|||||||
| Sales revenue | - | 43,035 | 282,439 | 106,759 | 228,416 | 168,753 | 185,414 |
| Profit before tax | 0 | -15,435 | 22,568 | 7,645 | 66,791 | 23,343 | 24,061 |
| Net profit | 0 | -15,435 | 22,164 | 7,219 | 63,351 | 21,485 | 23,648 |
| Equity | 1 | -15,434 | 10,910 | 18,129 | 81,480 | 102,965 | 87,613 |
| Liabilities | - | - | 33,033 | 33,369 | 904,107 | 537,841 | 499,573 |
| Non-current assets | 0 | 5,365 | 23,669 | 24,028 | 62,999 | 32,527 | 17,172 |
| Current assets | 10 | 10,053 | 20,128 | 27,407 | 922,508 | 606,853 | 568,687 |
| Total assets | 10 | 15,418 | 43,797 | 51,435 | 985,507 | 639,380 | 585,859 |
|
Taxes paid
|
|||||||
| STI taxes | - | - | - | - | 33,987 | 58,291 | 78,510 |
| Social insurance contributions | - | - | - | - | 6,497 | 38,219 | 46,209 |
|
Financial indicators
|
|||||||
| Revenue change y/y | - | - | +556.3% | -62.2% | +114.0% | -26.1% | +9.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 0.0% | -100.1% | 50.6% | 14.0% | 6.4% | 3.4% | 4.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 0.0% | - | 203.2% | 39.8% | 77.8% | 20.9% | 27.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | -35.9% | 7.8% | 6.8% | 27.7% | 12.7% | 12.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | -35.9% | 8.0% | 7.2% | 29.2% | 13.8% | 13.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | 3.0 | 1.8 | 11.1 | 5.2 | 5.7 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 19,127 | 43,452 | 19,411 | 46,457 | 18,244 | 19,181 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Genomika - Social security debts
The company had no debts to Sodra
Genomika - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-06-28 | 2025-06-28 | 0.39 |
| 2025-04-04 | 2025-04-04 | 2694.87 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Genomika, UAB (code 305251479) is a private limited liability company engaged in wholesale of other chemical products. In 2025, the company generated revenue of €185.4K and net profit of €23.6K, with a net profit margin of 12.8%. Revenue increased by 9.9% year on year from €168.8K in 2024, although it remained below the €228.4K recorded in 2023, showing a partial recovery after the decline in the prior year. Net profit followed a similar pattern: €63.4K in 2023, €21.5K in 2024 and €23.6K in 2025. The balance sheet in 2025 shows total assets of €585.9K, equity of €87.6K and liabilities of €499.6K. The equity ratio was 14.9%, while debt-to-equity stood at 5.70, indicating a leveraged capital structure. Asset turnover was 0.32x, ROE was 27.0% and ROA was 4.0%. Revenue per employee was €20.6K and profit per employee was €2.6K in 2025.